A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Clinical trial NCT07340658 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07340658
- Sponsor
- Rovi Pharmaceuticals Laboratories
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2029-02-01
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.